Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients

Annamaria Cattaneo, Clarissa Ferrari, Rudolf Uher, Luisella Bocchio-Chiavetto, Marco Andrea Riva, MRC ImmunoPsychiatry Consortium, Carmine M Pariante, Annamaria Cattaneo, Clarissa Ferrari, Rudolf Uher, Luisella Bocchio-Chiavetto, Marco Andrea Riva, MRC ImmunoPsychiatry Consortium, Carmine M Pariante

Abstract

Background: Increased levels of inflammation have been associated with a poorer response to antidepressants in several clinical samples, but these findings have had been limited by low reproducibility of biomarker assays across laboratories, difficulty in predicting response probability on an individual basis, and unclear molecular mechanisms.

Methods: Here we measured absolute mRNA values (a reliable quantitation of number of molecules) of Macrophage Migration Inhibitory Factor and interleukin-1β in a previously published sample from a randomized controlled trial comparing escitalopram vs nortriptyline (GENDEP) as well as in an independent, naturalistic replication sample. We then used linear discriminant analysis to calculate mRNA values cutoffs that best discriminated between responders and nonresponders after 12 weeks of antidepressants. As Macrophage Migration Inhibitory Factor and interleukin-1β might be involved in different pathways, we constructed a protein-protein interaction network by the Search Tool for the Retrieval of Interacting Genes/Proteins.

Results: We identified cutoff values for the absolute mRNA measures that accurately predicted response probability on an individual basis, with positive predictive values and specificity for nonresponders of 100% in both samples (negative predictive value=82% to 85%, sensitivity=52% to 61%). Using network analysis, we identified different clusters of targets for these 2 cytokines, with Macrophage Migration Inhibitory Factor interacting predominantly with pathways involved in neurogenesis, neuroplasticity, and cell proliferation, and interleukin-1β interacting predominantly with pathways involved in the inflammasome complex, oxidative stress, and neurodegeneration.

Conclusion: We believe that these data provide a clinically suitable approach to the personalization of antidepressant therapy: patients who have absolute mRNA values above the suggested cutoffs could be directed toward earlier access to more assertive antidepressant strategies, including the addition of other antidepressants or antiinflammatory drugs.

Keywords: cytokine absolute blood levels; personalized medicine; predictors; treatment response.

© The Author 2016. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Representative interaction between Macrophage Migration Inhibitory Factor (MIF) (Figure 1a) or interleukin (IL)-1β (Figure 1b) and their neighbors’ targets, where nodes (genes) can be either colored (if they are directly linked to the input, in that case MIF) or white (nodes of a higher interaction/depth-this is not the case). Lines represent predicted functional edges of interaction between nodes, and they are represented with eight different colors according to the type of evidence and the predictive method used (neighborhood, gene fusion, co-occurrence, coexpression, experiments, databases, and textmining): green line,activation; red line, inhibition; blue line, binding; light blue line, phenotype; violet, catalyzes; pink, posttranslational mechanism; black, reaction; yellow, coexpression (http://string-db.org).

References

    1. Abdel-Salam OM, Nofal SM, El-Shenawy SM. (2003) Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol Res 48:157–165.
    1. Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. (2006. ) Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 580:974–981
    1. Al-Amin MM, Uddin MM, Rahman MM, Reza HM, Rana MS. (2013. ) Effect of diclofenac and antidepressants on the inflammatory response in astrocyte cell culture. Inflammopharmacol 21:421–5. doi: 10.1007/s10787-013-0181-9.
    1. Alcocer-Gomez E, Cordero MD. (2014. ) NLRP3 inflammasome: a new target in major depressive disorder. CNS Neurosci Ther 20:294–295. doi: 101111/cns.12230.
    1. Anacker C, Cattaneo A, Luoni A, Musaelyan K, Zunszain PA, Milanesi E, Rybka J, Berry A, Cirulli F, Thuret S, Price J, Riva MA, Gennarelli M, Pariante CM. (2013. ) Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis. Neuropsychopharmacology 38:872–883. doi: 10.1038/npp.2012.253.
    1. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. (2010. ) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71:1565–1575. doi: 10.4088/JCP.09r05786blu. Review.
    1. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. (2015. ) Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol Psychiatry:2015 Jun 2.
    1. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC. (2012. ) Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185. doi: 10.1038/tp.2012.112.
    1. Bloom J, Al-Abed Y. (2014) MIF: mood improving/inhibiting factor? J Neuroinflammation 21:11. doi: 10.1186/1742-2094-11-11. Review.
    1. Bufalino C, Hepgul N, Aguglia E, Pariante CM. (2013. ) The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immun 31:31–47. doi: 10.1016/j.bbi.2012.04.009.
    1. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, Miyazaki C, Alexander N, Hotopf M, Cleare AJ, Norris S, Cassidy E, Aitchison KJ, Miller AH, Pariante CM. (2009. ) Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14:1095–1104. doi: 10.1038/mp.2008.48.
    1. Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulou K, Cleare AJ, Pariante CM. (2013) Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord 148:136–140. doi: 10.1016/j.jad.2012.10.036.
    1. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, Mcguffin P, Pariante CM. (2013. ) Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 38:377–385. doi: 10.1038/npp.2012.191.
    1. Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R. (2014. ) Childhood maltreatment and inflammatory markers: a systematic review. Acta Psychiatr Scand 129:180–192. doi: 10.1111/acps.12217.
    1. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. (2008. ) Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65:409–415. doi: 10.1001/archpsyc.65.4.409.
    1. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. (2007. ) Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A 104:1319–1324. doi: 10.1073/pnas.0610362104.
    1. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. (2010. ) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457. doi: 10.1016/j.biopsych.2009.09.033.
    1. Fan H, Hall P, Santos LL, Gregory JL, Fingerle-Rowson G, Bucala R, Morand EF, Hickey MJ. (2011. ) Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol 186:4915–4924. doi: 10.4049/jimmunol.1003713.
    1. Felger JC, Lotrich FE. (2013. ) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229. doi: 10.1016/j.neuroscience.2013.04.060.
    1. Fitzgerald P, O’brien SM, Scully P, Rijkers K, Scott LV, Dinan TG. (2006. ) Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 36:37–43. doi: 10.1017/S003329170500632X.
    1. Gregory JL, Morand EF, Mckeown SJ, Ralph JA, Hall P, Yang YH, Mccoll SR, Hickey MJ. (2006. ) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072–8079.
    1. Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. (2013) Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med 11:28. doi: 10.1186/1741–7015-11-28.
    1. Horowitz MA, Wertz J, Zhu D, Cattaneo A, Musaelyan K, Nikkheslat N, Thuret S, Pariante CM, Zunszain PA. (2014. ) Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells. Int J Neuropsychopharmacol. 18 pii: pyu076. doi: 10.1093/ijnp/pyu076.
    1. Howren MB, Lamkin DM, Suls J. (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186. doi: 10.1097/PSY.0b013e3181907c1b.
    1. Keers R, Uher R, Gupta B, Rietschel M, Schulze TG, Hauser J, Skibinska M, Henigsberg N, Kalember P, Maier W, Zobel A, Mors O, Kristensen AS, Kozel D, Giovannini C, Mendlewicz J, Kumar S, Mcguffin P, Farmer AE, Aitchison KJ. (2010. ) Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J Affect Disord 127:337–342. doi: 10.1016/j.jad.2010.06.011.
    1. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB, Holsboer F, Heim CM, Ressler KJ, Rein T, Binder EB. (2013. ) Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 16:33–41. doi: 10.1038/nn.3275.
    1. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. (2000. ) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22:370–379. doi: 10.1016/S0893-133X(99)00134-7.
    1. Leech M, Metz C, Bucala R, Morand EF. (2000. ) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 43:827–833. doi: 10.1002/1529-0131(200004)43:4<827::AID-ANR13>;2-K.
    1. Leemans JC, Cassel SL, Sutterwala FS. (2011. ) Sensing damage by the NLRP3 inflammasome. Immunol Rev 243:152–162. doi: 10.1111/j.1600-065X.2011.01043.x.
    1. Li X, Wang X. (2000. ) Application of real-time polymerase chain reaction for the quantitation of interleukin-1beta mRNA upregulation in brain ischemic tolerance. Brain Res Brain Res Protoc 5:211–217.
    1. Lisi L, Camardese G, Treglia M, Tringali G, Carrozza C, Janiri L, Dello Russo C, Navarra P. (2013. ) Monocytes from depressed patients display an altered pattern of response to endotoxin challenge. PLoS One 8:e52585. doi: 10.1371/journal.pone.0052585.
    1. Marschallinger J, Krampert M, Couillard-Despres S, Heuchel R, Bogdahn U, Aigner L. (2014. ) Age-dependent and differential effects of Smad7DeltaEx1 on neural progenitor cell proliferation and on neurogenesis. Exp Gerontol 57C:149–154. doi: 10.1016/j.exger.2014.05.011.
    1. Martinez JM, Garakani A, Yehuda R, Gorman JM. (2012. ) Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety 29:32–38. doi: 10.1002/da.20876.
    1. Mc Lachlan 2004. Discriminant analysis and statistical pattern recognition, Book
    1. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680–684.
    1. Nanni V, Uher R, Danese A. (2012. ) Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 169:141–151.
    1. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, Mccullough JP, Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. (2003. ) Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 100:14293–14296. doi: 10.1073/pnas.2336126100.
    1. Powell TR, Schalkwyk LC, Heffernan AL, Breen G, Lawrence T, Price T, Farmer AE, Aitchison KJ, Craig IW, Danese A, Lewis C, Mcguffin P, Uher R, Tansey KE, D’souza UM. (2013. ) Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur Neuropsychopharmacol 23:1105–1114. doi: 10.1016/j.euroneuro.2012.09.009.
    1. Radi E, Formichi P, Battisti C, Federico A. (2014. ) Apoptosis and Oxidative Stress in Neurodegenerative Diseases. J Alzheimers Dis. doi: 10.3233/JAD–132738.
    1. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. (2013. ) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41. doi: 10.1001/2013.jamapsychiatry.4.
    1. Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, Huebinger RM, Barber RC, Trivedi MH. (2013. ) Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 18:1119–1124. doi: 10.1038/mp.2012.125.
    1. Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J. (2015. ) The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 300, 141–154.doi: 10.1016/j.neuroscience.2015.05.018.
    1. Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, Jaffuel D, Mathieu M. (2007. ) Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 8:35. doi: 10.1186/1465-9921-8-35.
    1. Rush AJ, Thase ME, Dube S. (2003. ) Research issues in the study of difficult-to-treat depression. Biol Psychiatry 53:743–753.
    1. Santos LL, Fan H, Hall P, Ngo D, Mackay CR, Fingerle-Rowson G, Bucala R, Hickey MJ, Morand EF. (2011. ) Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum 63:960–970. doi: 10.1002/art.30203.
    1. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH. (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes JAMA Psychiatry 72:268–275.
    1. Sluzewska A, Sobieska M, Rybakowski JK. (1997. ) Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35:123–127.
    1. Sullivan PF, Fan C, Perou CM. (2006. ) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B:261–268. doi: 10.1002/ajmg.b.30272.
    1. Toh ML, Aeberli D, Lacey D, Yang Y, Santos LL, Clarkson M, Sharma L, Clyne C, Morand EF. (2006. ) Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 177:4818–4825.
    1. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. (2014. ) Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun 42:50–59.
    1. Trivedi MH. (2006. ) Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 67 Suppl 6:27–32.
    1. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. (2012. ) A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 26:469–79. doi: 10.1016/j.bbi.2011.12.011.
    1. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, Mcguffin P, Craig I. (2009. ) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9:225–233. doi: 10.1038/tpj.2009.12.
    1. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, Mcguffin P. (2010. ) Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167:555–564. doi: 10.1176/appi.ajp.2009.09070932.
    1. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, Mcguffin P. (2014. ) An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. Am J Psychiatry. doi: 10.1176/appi.ajp.2014.14010094.
    1. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret S, Price J, Pariante CM. (2012. ) Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37:939–949. doi: 10.1038/npp.2011.277.

Source: PubMed

3
订阅